Drug Profile
VK 0612
Alternative Names: MB 07803; VK-0612Latest Information Update: 16 May 2017
Price :
$50
*
At a glance
- Originator Metabasis Therapeutics
- Developer Viking Therapeutics
- Class Amino acids; Antihyperglycaemics; Oxazoles; Thiazoles
- Mechanism of Action Fructose bisphosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
Most Recent Events
- 21 Mar 2017 Viking Therapeutics has patent protection and a pending patent application for VK 0612 in USA, China, Hong Kong, Israel, Korea, Mexico, India, Indonesia and New Zealand
- 30 Jun 2015 VK 0612 is still in phase II trials for Type-2 diabetes mellitus in USA
- 22 May 2014 VK 0612 licensed to Viking Therapeutics worldwide